Six top tips to prepare for the new EU Clinical Trial Regulation

The European Union Clinical Trial Regulation 536/2014 (EU-CTR) aims to standardize and harmonize the conduct and management of interventional clinical trials across the European Economic Area (EEA), with legally binding rules on requirements and increased transparency. The new EU-CTR promises a simplified process designed to decrease the burden resulting from idiosyncratic interpretations of the current EU-CTD. But to reap efficiencies, sponsors must sow operational changes. This article covers the six essential preparations companies should undertake now.

Open PDF

Return to Insights Center

Related Insights


Expedited Pathways Comparisons - US EU CHN

Oct 19, 2021


Adoption of the ICH Q12 guideline: New Horizons for Efficient Product Supply Chain Management for a Key Global Market

Nov 13, 2023


Lessons from China and the United States on the use of RWE in regulatory submissions

Jul 19, 2021


Near-term strategies for biotech drug developers facing shifting healthcare dynamics

Feb 14, 2024


Australia: The Regulatory and Reimbursement Environment

Aug 28, 2023


Ensuring future success in a new market by delivering a robust safety database solution

Aug 4, 2023


Preparing for the New Era of Hybrid Regulatory Inspections

Jul 11, 2022


On-demand webinar: An expert guide to EU-CTR

Mar 10, 2022


New FDA Guidance Addresses the Need for Data-Generation Strategies Across the Drug Development Lifecycle

May 10, 2022


Maintaining Data Integrity for Quality and Compliance – Essential Despite Pandemic Disruptions

May 16, 2022


RBQM Podcast Series | Episode 3: Staying within the Guardrails: How to Push the Boundaries in a Highly Regulated Industry

Jun 16, 2022


8 things you need to know about eCTDs in China

Jul 1, 2022